BATON ROUGE, La., and BANNOCKBURN, Ill., Jan. 05, 2021 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and personal care, and Option Care Health Inc. (NASDAQ: OPCH), the nation’s largest independent home and alternate site infusion services provider, are collaborating on providing COVID antibody infusion therapy within skilled nursing and assisted living facilities, collectively referred to as “long term care facilities.” The U.S Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUAs) to both Eli Lilly and Regeneron for their investigational neutralizing antibody therapies to treat mild to moderate COVID-19 in adults and pediatrics who are at high risk for progressing to severe COVID-19 symptoms or hospitalization.

On December 8, 2020, the National Home Infusion Association (NHIA) announced it had launched a pilot program with Operation Warp Speed and the department of Health and Human Services to expand access to Bamlanivimab for COVID-19-positive eligible patients residing in long-term care facilities. As an active member of the NHIA, Option Care Health agreed to participate in the pilot program to help service this vulnerable population.

Through the collaboration, which will initially be piloted in Indianapolis and Valparaiso, Indiana markets, with potential to scale to other markets, as appropriate, Amedisys and Option Care Health will coordinate to expeditiously provide care to long-term care facility residents. This innovative service model draws on the strengths and capabilities of both organizations and leverages clinical resources in the most efficient way to ensure expanded access to this difficult-to-serve population. Through its Hospice division, Amedisys will oversee the on-site care coordination for residents through their expansive clinical team. Option Care Health will leverage its pharmacy network operations to provide critical clinical pharmacy oversight and will distribute Bamlanivimab through its national network of pharmacies.

John Rademacher, Chief Executive Officer of Option Care Health, stated, “We are proud to collaborate with Amedisys, a leader in home health and hospice services, along with NHIA and leaders of Operation Warp Speed, to expand access to vital therapies for one of the most vulnerable populations. Combining the extraordinary capabilities of two industry leaders to solve a critical healthcare challenge is truly humbling.”   

“We have experience from being on the frontlines and caring for more than 12,500 COVID 19-positive patients,” stated Paul Kusserow, President and Chief Executive Officer of Amedisys. “We know how important innovative solutions are for caring for those who need our services the most, and this is exactly the type of partnerships in which Amedisys wants to be involved to help our country make it through this pandemic. We’re extremely honored to play our part alongside Option Care Health, NHIA and Operation Warp Speed.”

About Amedisys

Amedisys, Inc. is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, Tenn., Amedisys is a publicly held company. With 21,000 employees in 514 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

Sobre Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates.

Forward-Looking Statements:
When included in this press release, words like “believes,” “belief,” “expects,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “would,” “should,” “will” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disasters or acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions, and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

For Investor Inquiries:
Bob East, Asher Dewhurst, Jordan Kohnstam
Westwicke
443-213-0500
optioncarehealth@westwicke.com 

La primera opción de tratamiento sin cirugía para el cáncer de tracto urinario poco frecuente y difícil de tratar requiere un protocolo clínico complejo

BANNOCKBURN, Ill., May 21, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health” or the “Company”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, has been selected by UroGen Pharma (NASDAQ: URGN) as a preferred national pharmacy provider to prepare and deliver a first-of-its-kind cancer treatment, Jelmyto™ (mitomycin) for pyelocalyceal solution.

La nueva formulación ofrece un enfoque novedoso para el tratamiento de adultos con cáncer urotelial de bajo grado en el tracto superior (LG-UTUC), que se dirige directamente a tumores con un medicamento que cambia de forma a medida que se calienta y debe ser proporcionado por el médico en un plazo de ocho horas después de su preparación. Para garantizar que el medicamento se prepare, envíe y suministre al paciente en el plazo requerido y de conformidad con los requisitos de las indicaciones de uso del producto y las normas de la farmacia, Option Care Health se asoció con UroGen para crear una solución farmacéutica innovadora para apoyar a Jelmyto a través de su farmacia de fórmulas magistrales estériles y su red de distribución en todo el país.

Aprobado por la Administración de Alimentos y Medicamentos de los Estados Unidos el 15 de abril de 2020, Jelmyto es un tratamiento primero en su tipo que consiste en mitomicina (una quimioterapia de eficacia comprobada) e hidrogel estéril que utiliza la tecnología patentada de liberación sostenida RTGel™ de UroGen. Se ha diseñado para permitir una exposición más prolongada del tejido del tracto urinario a la mitomicina, facilitando el tratamiento de estos tumores cancerosos poco frecuentes y difíciles de tratar con una opción no quirúrgica y de conservación del riñón.

Jelmyto debe prepararse en farmacias que cumplan con la norma USP 800 y que utilicen normas de calidad y seguridad más estrictas y, además de las salas de formulación, deben contar con capacidad y experiencia ampliadas para procesar componentes de medicamentos citotóxicos. La red nacional de farmacias USP 800 de Option Care Health preparará la fórmula de conformidad con las recetas de Jelmytoespecíficas para el paciente y la entregará al urólogo en el plazo requerido y de conformidad con las rigurosas normas de las Instrucciones de Jelmyto para la farmacia.  

"La infraestructura y las capacidades de formulación de Option Care Health en nuestra red de farmacias que cumplen con la norma USP 800 son incomparables, lo que nos permite ofrecer servicios integrales en colaboración con UroGen", afirmó John C. Rademacher, Presidente y Director General de Option Care Health. "Cada día, Option Care Health garantiza que miles de pacientes reciban las terapias necesarias de manera segura y oportuna. Las inversiones que hemos hecho en nuestra infraestructura clínica nos permiten asociarnos con UroGen para ofrecer esta nueva e innovadora terapia".

“UroGen desafía el estándar de atención a través de novedosas alternativas de tratamiento no quirúrgicas, como Jelmyto, que aprovecha nuestra innovadora tecnología y experiencia en cánceres y enfermedades urológicas de especialidad”, afirmó Liz Barrett, presidenta y directora ejecutiva de UroGen. “Jelmyto requiere una preparación compleja y una entrega oportuna, y Option Care Health ofrece la escala nacional, la amplia experiencia, el conocimiento especializado y el compromiso con la calidad que requerimos en un socio para garantizar que los pacientes reciban esta nueva terapia vital de manera oportuna y segura”.

El cáncer urotelial de bajo grado en el tracto superior (LG-UTUC) es un cáncer poco frecuente que se desarrolla en el endotelio del tracto urinario superior, los uréteres y los riñones. Cada año, aproximadamente de 6,000 a 7,000 pacientes de Estados Unidos son diagnosticados con LG-UTUC nuevo o recurrente. Este cáncer es difícil de tratar debido a la compleja anatomía del sistema del tracto urinario. El estándar actual de atención incluye múltiples cirugías y a menudo una nefroureterectomía radical, incluyendo la extirpación de la pelvis renal, el riñón, el uréter y la cúpula de la vejiga.

About Option Care Health

Option Care es el proveedor independiente de servicios de infusión a domicilio y en centros alternativos de tratamiento más grande del país. Con más de 5,000 compañeros de equipo, incluidos 2,900 médicos, trabajamos con compasión para elevar los estándares de atención para pacientes con afecciones agudas y crónicas en los 50 estados. A través de nuestro liderazgo clínico, experiencia y escala nacional, Option Care Health está reinventando la experiencia de la atención con terapia de infusión para pacientes, clientes y empleados. Para conocer más, visite nuestro sitio web en OptionCareHealth.com.

Acerca de UroGen Pharma Ltd.
UroGen es una empresa biofarmacéutica dedicada a crear soluciones innovadoras para tratar cánceres y enfermedades urológicas de especialidad porque los pacientes merecen mejores opciones. UroGen ha desarrollado el hidrogel termoinvertido RTGel™, una tecnología patentada de plataforma de liberación prolongada basada en hidrogel que tiene el potencial de mejorar los perfiles terapéuticos de los fármacos existentes. La tecnología de liberación prolongada de UroGen está diseñada para permitir una exposición más prolongada del tejido del tracto urinario a los medicamentos, lo que convierte a la terapia local en una opción de tratamiento potencialmente más eficaz. El medicamento Jelmyto™ (mitomicina) aprobado de UroGen para solución pielocalicial, y el tratamiento de conductos UGN-102 (mitomicina) para solución intravesical están diseñados para extirpar tumores por medios no quirúrgicos y tratar varias formas de cáncer urotelial invasivo no muscular, incluidos cáncer urotelial de bajo grado de tracto superior y cáncer de vejiga invasivo de bajo grado no muscular, respectivamente. UroGen tiene su sede en Princeton, Nueva Jersey, con operaciones en Israel. Visite www.urogen.com para obtener más información o síganos en Twitter, @UroGenPharma.

Declaraciones prospectivas - Limitación de responsabilidad

Este comunicado de prensa puede contener “declaraciones prospectivas" dentro del significado de las disposiciones sobre refugio tributario de la Ley de Reforma de Litigios de Valores Privados de Estados Unidos de 1995. Las declaraciones prospectivas pueden identificarse con palabras como: "anticipar", "pretender", "planificar", "creer", "proyectar", "estimar", "esperar", "puede", "debería", "hará" y otras referencias similares al futuro. Algunos ejemplos de declaraciones prospectivas incluyen, entre otros, las declaraciones que podamos hacer con respecto a ingresos futuros, ganancias futuras, desarrollos reglamentarios, desarrollos del mercado, nuevos productos y estrategias de crecimiento, actividades de integración y los efectos de cualquiera de los anteriores en los resultados futuros de nuestras operaciones o condiciones financieras.

Las declaraciones prospectivas no son hechos históricos ni garantías de desempeño futuro. En cambio, se basan solo en nuestras creencias, expectativas y suposiciones actuales con respecto al futuro de nuestro negocio, planes futuros y estrategias, proyecciones, eventos anticipados y tendencias, la economía y otras condiciones futuras. Debido a que las declaraciones prospectivas se relacionan con el futuro, están sujetas a incertidumbres, riesgos y cambios inherentes en circunstancias que son difíciles de predecir y muchas de las cuales están fuera de nuestro control. Nuestros resultados y nuestro estado financiero reales pueden diferir materialmente de los indicados en las declaraciones prospectivas. Los factores importantes que podrían hacer que nuestros resultados reales y nuestro estado financiero difieran sustancialmente de los indicados en las declaraciones prospectivas incluyen, entre otros, los siguientes: (i) cambios en las leyes y reglamentos aplicables a nuestro modelo de negocio; (ii) cambios en las condiciones del mercado y en la receptividad a nuestros servicios y ofertas; (iii) resultados de litigios; y (iv) la pérdida de uno o más pagadores clave; y (v) la diseminación y el impacto de la pandemia de COVID-19. Para ver un análisis detallado de los factores de riesgo que podrían afectar nuestros resultados reales, consulte los factores de riesgo identificados en nuestros informes a la SEC, incluido, entre otros, nuestro informe anual en el formulario 10-K y los informes trimestrales en el formulario 10-Q, tal como se presentaron a la SEC.

Cualquier declaración prospectiva hecha por nosotros en este comunicado de prensa se basa únicamente en la información disponible actualmente para nosotros y solo se refiere al estado a la fecha en la que se emite. No asumimos ninguna obligación de actualizar públicamente ninguna declaración prospectiva, ya sea escrita u oral, que pueda hacerse ocasionalmente, ya sea como resultado de información nueva, desarrollos futuros o de otro tipo.

Ensuring Patient Safety and Continuity of Care is Key During COVID-19 Public Health Crisis as Hospitals Face Unprecedented Challenges

BANNOCKBURN, Ill., April 22, 2020 –  Regence and Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH) today announced an expanded partnership to ease access to care and provide additional options for high-risk patients who rely on infusion therapy. This collaboration enables Regence Health Plan members who currently receive their infusion therapy services in a hospital outpatient setting the ability to transition care to their home or an Option Care Health Infusion Suite.

Regence is committed to helping ease the burden on hospitals during the COVID-19 pandemic and ensuring its members and their families have the clinical care support they need, provided in the comfort, convenience and safety of a preferred location. Regence is a family of health plans in Oregon, Idaho, Utah and select counties in Washington, each an independent licensee of the Blue Cross and Blue Shield Association dedicated to making healthcare better, simpler and more affordable.

“Ensuring our members have convenient access to care in a safe and affordable setting is our top priority,” said Kerry Bendel, Regence’s Chief Pharmacy Officer. “Option Care Health’s 40-years of experience focused solely on infusion therapy makes them the right partner to help protect the health and safety of our members, their families and our community during the unprecedented challenges created by the COVID-19 crisis.”

The partnership – which builds on Regence’s existing Site of Care program – helps address changing needs during the COVID-19 pandemic, allowing for greater flexibility for hospitals, physicians and patients who rely on infusion therapies for a wide variety of acute and chronic needs, from nutrition support and immune disorders to infections and neurologic conditions.

“Infusion provided safely and effectively at home or an infusion suite is more vital to our nation’s health system and patients than ever before,” said John C. Rademacher, President and Chief Executive Officer of Option Care Health. “As we face this public health crisis, it is critical that we work together to continue delivering trusted clinical care that expands the overall capacity of our healthcare system.”

Option Care Health sigue rigurosas pautas de los Centros para el Control y la Prevención de Enfermedades (CDC) para garantizar la seguridad de los pacientes y el personal. Estas medidas incluyen capacitación integral de los empleados, protocolos estrictos para el control de infecciones en el hogar y en las salas de infusión, evaluación del personal y de los pacientes para detectar síntomas de COVID-19, actualizaciones y educación continua sobre virus y el uso de equipos de protección personal (EPP). Los empleados pueden llamar a la línea directa de COVID-19 de Option Care Health las 24 horas del día, los 7 días de la semana para abordar preguntas sobre su salud o la salud de un paciente.

Care managers and clinicians will contact high-risk Regence members to ensure they know about the option to receive infusion therapy care in an alternate setting. Option Care Health clinical teams will coordinate transitions of care and customize treatment plans to suit the specific needs of each patient, with an assigned nurse and pharmacist to monitor treatment. Experienced clinicians and nurses are available 24 hours a day, seven days a week, 365 days a year to answer questions and provide support for patients, families and providers.

For more information on the Option Care Health and Regence response to the COVID-19 pandemic, visit optioncarehealth.com/coronavirus and regence.com/member/health-lifestyle/coronavirus-covid-19.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.

About Regence

Regence serves approximately 3.1 million members through Regence BlueShield of Idaho, Regence BlueCross BlueShield of Oregon, Regence BlueCross BlueShield of Utah and Regence BlueShield (select counties in Washington). Each health plan is a nonprofit independent licensee of the Blue Cross and Blue Shield Association. Regence is part of a family of companies dedicated to transforming healthcare by delivering innovative products and services that change the way consumers nationwide experience healthcare. For more information, please visit Regence.com.

La experiencia clínica y la escala nacional del proveedor de atención de infusión garantizan una atención de alta calidad en un entorno de menor riesgo

BANNOCKBURN, Ill., April 14, 2020 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, is on the frontlines of the COVID-19 pandemic, working in collaboration with our nation’s hospitals and their clinical teams to ensure patients continue to receive vital care. Option Care Health provides essential infusion services that enable patients to transition home from the hospital sooner, freeing up beds for critically ill COVID-19 patients.

Serving patients in all 50 states, Option Care Health is easing the burden on strained health systems in critical markets. Physicians and patients rely on infusion therapies for a wide variety of acute and chronic needs, from nutrition support and immune disorders to infections and neurologic conditions. Option Care Health is a critical part of the pandemic response, developing unique solutions that safely transition patients requiring infusion therapy out of the hospital – flexing capacity by deploying and shifting resources where the need is the greatest and utilizing the more than 125 infusion sites it operates across the country.

“We are fighting this pandemic side by side with our health system partners, fully prepared and able to support the needs of their patients who can transition home to continue their therapy. Whether they are in pre-plan preparation or already at surge capacity in a pandemic hotspot, our team is responding quickly and effectively to meet their needs,” said Harriet Booker, Chief Operating Officer of Option Care Health. “We’re not missing a beat. If our partners need us to accommodate a 10 p.m. bedside discharge for a patient on IV antibiotics medication, transfer a rheumatoid arthritis patient from a hospital-based ambulatory care center or virtually discharge an immunocompromised patient to reduce the risk of COVID-19 transmission, we’re where they need us to be.”

La red integral de Option Care Health y los planes de continuidad de negocios garantizan su capacidad para brindar atención de enfermería y farmacia que ofrece terapia de infusión a los pacientes de manera constante y confiable en todo el país. Esta agilidad en tiempo real requiere turnos adicionales, rotaciones de personal a distancia y horas de farmacia ampliadas para preparar y administrar medicamentos vitales". Además, Option Care Health tiene la capacidad de reasignar recursos clínicos a las ciudades con mayor necesidad.

Option Care Health has implemented rigorous protocols to ensure the safety of patients and staff working directly with its infectious disease experts and following Centers for Disease Control and Prevention (CDC) guidelines. These measures include comprehensive training of employees, strict protocols for infection control at home and infusion suites, screening of staff and patients for COVID-19 symptoms, ongoing virus-specific updates and education and the use of personal protection equipment (PPE). Staff members can call an Option Care Health COVID-19 hotline 24/7 to address questions regarding their health or a patient’s health. 

“Infusion at home or an infusion suite is a safe and effective care setting that is even more vital during times of national emergency, such as the current COVID-19 crisis,” said John C. Rademacher, President and Chief Executive Officer of Option Care Health. “Our highly skilled team of healthcare professionals provide infusion services that deliver hope to patients and physicians by easing the burden on hospital inpatient census, while lowering the patient’s risk and ensuring they receive excellent care after they are discharged.”

Option Care Health’s clinical team, consisting of 2,900 nurses, dietitians and pharmacists, annually care for more than 220,000 patients of all ages. The Option Care Health clinical team elevates the infusion therapy experience through customized care plans specific to every patient. Experienced clinicians and nurses are available 24 hours a day, seven days a week, 365 days a year to answer questions and provide support for patients, families and providers.

For more information on Option Care Health’s response to the COVID-19 pandemic, visit  optioncarehealth.com/coronavirus.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is re-imagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at OptionCareHealth.com.

Largest Independent Home and Alternate Site Infusion Provider Establishes the Standard of Care Across the United States Through Its Clinical Leadership and Technology-Enabled Modelo centrado en el paciente

BANNOCKBURN, Ill. & DENVER, 7 de agosto de 2019: Option Care Enterprises, Inc. (“Option Care”) y BioScrip, Inc. (“BioScrip”) anunciaron hoy la finalización exitosa de su fusión, que sigue a que se cumplieron las condiciones de cierre de la transacción, incluida la aprobación por parte de los accionistas de BioScrip y la recepción de todas las aprobaciones regulatorias necesarias.

The newly combined company, Option Care Health, Inc. (“Option Care Health” or the “Company”), emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

John Rademacher, director ejecutivo de Option Care Health, dijo: “El día de hoy marca el comienzo de un nuevo y emocionante capítulo en el que unimos dos organizaciones sólidas con orgullosos antecedentes como líderes del mercado. Esta combinación nos permite reinventar la experiencia de la atención de infusión para liberar todo el potencial de una atención de alta calidad en un entorno de menor costo a escala nacional. Ahora somos el único proveedor independiente enfocado en brindar un espectro completo de terapias de infusión a pacientes en todo el país. Nuestra gran experiencia clínica, nuestra amplia cartera de terapias y nuestro mejor perfil financiero nos permiten ofrecer resultados superiores y establecer el estándar para la atención del paciente".

Option Care Health seguirá centrándose en lo siguiente:

• Patient-Centered Care Model, providing deeply personalized care to patients in all 50 states, supported by the broadest commercial and clinical coverage with our unique product offering.
• Clinical and Market Leadership, leveraging our best-in-class clinical team to consistently raise quality standards and patient outcomes while collaborating with health systems, payers and manufacturers to broaden our therapy portfolio and clinical reach.
• Invertir en personas, tecnología y operaciones para impulsar un crecimiento rentable, al tiempo que establece el estándar de la industria para los servicios de infusión.

Daniel E. Greenleaf, former Chief Executive Officer of BioScrip, commented, “I’m proud of the BioScrip team and the care that we delivered every day to patients who trusted us to provide extraordinary care. This new enterprise combines two independent market leaders and enables the organization to truly redefine infusion therapy in the alternate site setting. With a significantly improved capital structure and financial profile, I’m confident Option Care Health will continue to build upon the momentum of BioScrip and Option Care.”

Option Care Health tendrá su sede en Bannockburn, Illinois y estará dirigida por Rademacher como director ejecutivo y Mike Shapiro como director financiero. Harry Kraemer, expresidente y director ejecutivo de Baxter International Inc., se desempeñará como presidente del consejo de Option Care Health.

Advisors

In connection with the transaction, Jefferies LLC and Moelis & Company LLC acted as joint financial advisors to BioScrip, and Gibson, Dunn & Crutcher LLP served as legal advisor. Goldman Sachs & Co. LLC and BofA Merrill Lynch acted as financial advisors and Kirkland & Ellis LLP acted as legal advisor to Option Care.

Declaraciones prospectivas

This communication contains “forward-looking statements ” (as defined in the Private Securities Litigation Reform Act of 1995) regarding, among other things, future events or the future financial performance of Option Care Health. All statements other than statements of historical facts are forward-looking statements. In addition, words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words, and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements.

Forward-looking statements relating to Option Care Health include, but are not limited to: statements about the benefits of the combined company, including future financial and operating results; expected synergies; Option Care Health’s plans, objectives, expectations and intentions; and other statements relating to the merger that are not historical facts. Forward-looking statements are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections.

Se advierte a los inversionistas que todas estas declaraciones prospectivas están sujetas a riesgos e incertidumbres (que se conocen como no), y muchos factores podrían causar que los eventos o resultados reales difieran sustancialmente de los indicados en dichas declaraciones prospectivas. Con respecto a la combinación de BioScrip y Option Care, estos factores podrían incluir, entre otros: (i) el impacto que la deuda significativa incurrida en relación con la fusión pueda tener en la capacidad de Option Care Health para operar el negocio combinado, (ii) los riesgos relacionados con la integración de las operaciones, las soluciones y los empleados de BioScrip y Option Care en la empresa combinada y la posibilidad de que las sinergias esperadas y otros beneficios de la combinación, incluidos los ahorros de costos, no se realicen o no se realicen dentro del plazo previsto, (iii) el estado de Option Care Health como una "empresa controlada" en el sentido que establece Nasdaq, incluida la dependencia de Option Care Health de las exenciones de ciertos estándares de gobierno corporativo y la influencia mucho menor que los tenedores anteriores a la fusión tienen ahora en Option Care Health, y (iv) riesgos relacionados con los negocios combinados y las industrias en las que opera la compañía combinada.

Estos riesgos e incertidumbres, así como otros riesgos e incertidumbres, se analizan con más detalle en la declaración de poderes definitiva de BioScrip presentada ante la SEC el 26 de junio de 2019 y las presentaciones posteriores de Option Care Health ante la SEC. Aunque las listas de factores de riesgo presentadas aquí y en las presentaciones públicas de Option Care Health se consideran representativas, tal lista no debe considerarse una declaración completa de todos los riesgos y las incertidumbres potenciales. Muchos de estos riesgos, incertidumbres y suposiciones exceden la capacidad de control o predicción de BioScrip y Option Care. Debido a estos riesgos, incertidumbres y suposiciones, no debe depositar una confianza indebida en estas declaraciones prospectivas. Además, las declaraciones prospectivas se refieren solo a la información actualmente disponible para las partes en la fecha en que se realizan, y ni BioScrip ni Option Care asumen ninguna obligación de actualizar públicamente o de revisar las declaraciones prospectivas para reflejar eventos o circunstancias que puedan surgir después de la fecha de esta comunicación.

Sobre Option Care Health

En Option Care Health, Inc. (Option Care Health) (NASDAQ: BIOS), somos el mayor proveedor independiente de servicios de infusión en el hogar y en sitios alternativos en los Estados Unidos. Con más de 6,000 compañeros de equipo, incluidos 2,900 médicos, trabajamos con compasión para elevar los estándares de atención para pacientes con afecciones agudas y crónicas en los 50 estados. A través de nuestro liderazgo clínico, experiencia y escala nacional, Option Care Health está reinventando la experiencia de la atención con terapia de infusión para pacientes, clientes y empleados. Para conocer más, visite nuestro sitio web en OptionCareHealth.com.

For Media Inquiries:

Rachel Bowen, PCI

312.558.1770

RBowen@pcipr.com

For Investor Inquiries:

Mike Shapiro, director financiero

Option Care Health

312.940.2538

Investor.relations@optioncare.com

Option Care Enterprises, Inc., el proveedor líder en el país de servicios de terapia de infusión en el hogar y en centros alternativos, celebró hoy la apertura de su nuevo y moderno Centro de gestión de atención (CMC) en Atlanta. Los asistentes al corte de listón y ceremonia pública tuvieron la oportunidad de recorrer el nuevo centro, que cuenta con la tecnología y los equipos de infusión más modernos en un ambiente acogedor y confortable.

Al atender a pacientes que dependen de terapias de infusión complejas para tratamientos antiinfecciosos, apoyo nutricional clínico, terapia con inmunoglobulina y afecciones como trastornos inflamatorios crónicos y trastornos hemorrágicos, el CMC brindará atención a aproximadamente 1,000 pacientes en su hogar o en la sala de infusión ambulatoria (AIS). El nuevo centro no solo expande la capacidad de Option Care para brindar servicios de atención vital a más pacientes en el área de Atlanta, sino que su farmacia de servicio completo y su sala de preparación de compuestos estériles cumplen y superan las normas regulatorias actuales.

El CMC brinda acceso conveniente a atención y asistencia clínica excepcional a través de:

• Farmacia de infusión de servicio completo y manejo clínico de pacientes, incluidas la preparación y la administración de medicamentos para garantizar que cada paciente reciba el medicamento adecuado en la dosis adecuada con monitoreo adecuado y asistencia telefónica las 24 horas del día, los 7 días de la semana, con profesionales clínicos disponibles para responder preguntas a pacientes/cuidadores y proveedores.
• Sala de infusión ambulatoria con tres sillas de infusión en cubículos privados donde los pacientes pueden recibir sus tratamientos administrados por enfermeros altamente capacitados específicamente en terapia de infusión.
• Asistencia en el registro de pacientes, opciones de programación flexibles, incluidas las tardes y los fines de semana, estacionamiento gratuito en el lugar y fácil acceso a las instalaciones.

“Este nuevo CMC de Option Care en Peachtree Corners ofrece a los pacientes otra opción de terapia, ya sea que deseen recibir sus servicios de infusión en un centro nuevo y moderno, o en la comodidad de su propio hogar. El diseño no solo es estéticamente agradable, sino que está construido para ser el estándar de oro en instalaciones de preparación estéril”, afirmó el médico con sede en Atlanta, Anson Kwame Wurapa, M.D., quien visitó recientemente el CMC.

Muchos pacientes prefieren recibir sus infusiones en la comodidad de su hogar con la asistencia de los equipos de atención clínica de Option Care. Sin embargo, la infusión en el hogar puede no ser adecuada para todas las personas debido a una variedad de factores, incluidas la preferencia personal de estar lejos de casa para sus terapias, la falta de un entorno adecuado para el tratamiento en el hogar, las comorbilidades que requieren estar cerca de un equipo de atención completa y las limitaciones de la cobertura del seguro médico. El CMC de Option Care en Atlanta está equipado para ayudar a todos los pacientes de infusión en el área, ya sea que estén recibiendo tratamiento en casa o en la sala de infusión ambulatoria.

“Este nuevo CMC es lo mejor de todo lo que Option Care ofrece a los pacientes. Sabemos que estas terapias esenciales hacen posible que los pacientes disfruten de vitalidad y calidad de vida, y estamos encantados de poder brindárselas a más pacientes en el área de Atlanta”, afirmó John Rademacher, director ejecutivo de Option Care. “Este nuevo CMC representa nuestro compromiso de proveer atención clínica excepcional a través de los mejores profesionales clínicos e instalaciones disponibles”.

El CMC de Atlanta estará equipado para brindar resultados superiores con los servicios y programas de vanguardia, impulsados por la tecnología y basados en datos de Option Care.

Acerca de Option Care

Option Care Enterprises, Inc. (Option Care) es el proveedor de servicios de infusión en el hogar y en centros alternativos de tratamiento, más grande y más confiable del país. Con acreditaciones de organizaciones de calidad de la industria ACHC, PCAB, ASHP y URAC,[*]Comisión de Acreditación para Atención de Salud (ACHC), Junta de Acreditación de Farmacias de Compuestos (PCAB), Asociación Estadounidense de Farmacéuticos del Sistema de Salud (ASHP) y URAC, la compañía recurre a más de 40 años de experiencia en atención clínica para ofrecer manejo de terapia centrada en el paciente.

Los servicios distintivos de Option Care, Infusion Therapy Plus, comprenden la administración clínica de los medicamentos de infusión, el apoyo de enfermeros y la coordinación de la atención. El equipo multidisciplinario de más de 1,700 profesionales clínicos de Option Care —formado por farmacéuticos, enfermeros y nutricionistas— puede proporcionar cobertura de servicios de infusión en el hogar para casi todos los pacientes en los Estados Unidos que necesiten tratamiento para afecciones complejas y crónicas. Conozca más en www.OptionCareHealth.com.

PHOENIX, March 21, 2019 — Clinical interventions provided by a nutrition support team can prevent hospital readmission in patients with short bowel syndrome (SBS) receiving home parenteral nutrition (PN), saving millions in costs annually, suggests a study[*]Englert M, Stodola K. Proactive Interventions by Nutrition Support Clinicians in Patients with Short Bowel Syndrome (SBS) on Home Parenteral Nutrition (HPN) Results in Decreased Hospitalizations and Improved Financial Outcomes. Abstract presented at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2019 Nutrition Science & Practice Conference; March 23-26, 2019, Phoenix. by Option Care Enterprises, Inc. ( “Option Care”), the nation’s leading provider of home and alternate site infusion therapy services. The research is being presented at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2019 Nutrition Science & Practice Conference and was chosen as an Abstract of Distinction.

Among SBS patients receiving home PN provided intravenously (IV), dehydration is a common cause of hospital readmission, with an average three-day length of stay. In the study, the nutrition support team — including a dietitian, nurse and pharmacist — made recommendations (interventions) to adjust the home PN volume based on the weekly monitoring of patients’ hydration status through reviewing laboratory values and conducting nutrition assessments.

“Home nutrition patients on PN with SBS need to be observed closely the first month to prevent dehydration and making appropriate adjustments to the home PN volume is essential,” said Mary Englert, MS, RD, CSO, LDN, CNSC, Area Lead, Nutrition Support Dietitian at Option Care and lead author of the study. “Every intervention decreases the likelihood of the patient being readmitted to the hospital and this study highlights the value of a nutrition team in providing clinical monitoring and nutrition support, which leads to improved patient care and significant cost savings.”

The study included 116 patients with SBS who received home PN after being discharged from the hospital. The Registered Dietitian-led nutrition support team provided ongoing evaluation by reviewing labs weekly and conducting a thorough nutrition assessment, recommending adjustments to the volume of PN when indicated for a total of 63 proactive interventions during the four-week review period. The most common reasons for home PN volume adjustments were: to meet the patient’s estimated fluid needs (56 percent); lab values reflecting dehydration (22 percent) and increased gastrointestinal output (22 percent).

Only 14 of the study patients were readmitted to the hospital within two weeks of discharge, none resulting from dehydration. Readmissions were due to: abscess/infection not related to PN (35.7 percent); line infection/replacement (21.4 percent); bowel obstruction (14.3 percent) and nausea/vomiting, feeding tube replacement, chest pain and unknown (7.1 percent each).

The researchers determined the interventions correlated to 189 hospital days prevented and $378,000 in costs saved in one month. Projected over one year that equates to 2,268 hospital days prevented and over $4.5 million in savings.

Also presented at ASPEN:

In another Option Care study[*]Hughey M, Corey B. Early Clinical Intervention Increases Compliance and Decreases Unnecessary Discontinuation in SBS Patients treated with Teduglutide. Abstract presented at the American Society for Parenteral and Enteral Nutrition (ASPEN) 2019 Nutrition Science & Practice Conference; March 23-26, 2019, Phoenix. presented at ASPEN, 162 SBS patients were proactively screened for appropriate dosing before receiving teduglutide, which helps increase fluid and nutrient absorption resulting in decreased dependence on Parenteral Support. The clinical intervention resulted in recommended reductions to the prescribed dose in 64 of the patients (40 percent), half of which were based on impaired kidney function. Ensuring patients receive the appropriate dose reduces potential therapy complications including fluid overload, worsening kidney function and premature therapy discontinuation.

Acerca de Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s leading and most trusted provider of home and alternate site infusion therapy services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP and URAC,[*]Accreditation Commission for Health Care (ACHC), Pharmacy Compounding Accreditation Board (PCAB), American Society of Health-System Pharmacists (ASHP) and URAC the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature infusion services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.

Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Portfolio

Enhanced Scale and Improved Financial Profile Expected to Enable Growth in Attractive and Growing Segment of U.S. Healthcare Market

BioScrip to Issue New Shares to Option Care’s Shareholder, Which Will Own Approximately 80% of Combined Company on Fully Diluted Basis

Combined Company Will Remain Focused on Delivering Favorable Outcomes for Patients, Payors and Providers

DENVER and BANNOCKBURN, Ill., March 15, 2019 —  BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip”) and Option Care Enterprises, Inc. (“Option Care”), the nation’s largest independent providers of home and alternate treatment site infusion therapy services, today announced that they have entered into a definitive merger agreement. The combination is expected to create a leading independent provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market.

Según los términos del acuerdo de fusión, BioScrip emitirá nuevas acciones al accionista de Option Care, que es propiedad de fondos de inversión afiliados a Madison Dearborn Partners, LLC (“MDP”) y Walgreens Boots Alliance, Inc. (NASDAQ: WBA) (“WBA”), en una transacción con todas las acciones. Una vez completada la transacción, los fondos de MDP y WBA tendrán en usufructo aproximadamente el 80 % de la empresa combinada que cotiza en bolsa con un efecto total de reducción en el valor de los títulos, y los accionistas actuales de BioScrip tendrán el resto. Las acciones ordinarias de la empresa combinada continuarán cotizando en el mercado de valores global Nasdaq. La transacción ha sido aprobada por unanimidad por los consejos administrativos de BioScrip y Option Care.

The combined company will be led by Option Care Chief Executive Officer John Rademacher and Option Care Chief Financial Officer Mike Shapiro and will incorporate the best talent, processes and systems from both Option Care and BioScrip. It also will have a leading, independent clinical platform for delivering high-quality infusion therapy to more patients across the United States and providing superior outcomes for patients, payors and providers. BioScrip President and Chief Executive Officer Daniel E. Greenleaf will remain active in the combined company as a special advisor to its Board of Directors.

Daniel E. Greenleaf, President and Chief Executive Officer of BioScrip, commented, “This is a compelling and complementary fit of two leading players in the U.S. infusion market. Together, we will be able to provide a diverse set of life-improving and cost-effective services to more patients across the United States. Our expanded reach and broader array of offerings provide a key competitive advantage at a time when the demand for home and alternate site infusion services continues to grow. The BioScrip Board and I believe our shareholders will have the compelling opportunity to participate alongside Option Care’s experienced and seasoned shareholders in the long-term potential and value creation opportunities of the combined company.”

John Rademacher, Chief Executive Officer at Option Care, said, “This transaction brings together two organizations and thousands of employees dedicated to creating a best in class experience for our patients and their families. Our goal is to constantly improve the delivery of life-saving therapies and comprehensive care management to the patients we have the privilege of serving. At the center of both organizations is deep clinical expertise and a passion to deliver extraordinary care. We believe combining our unique assets and leading product portfolios will create a powerful, independent platform that will enable delivery of high-quality, cost effective solutions to providers across the country and help facilitate the introduction of innovative new therapies to the marketplace. As an independent provider, we will retain the unique ability to deliver high-quality infusion therapy in the patient-preferred and safer setting of the home or an alternate site to every commercial and governmental payor.

“I am honored to lead the combined company and work with BioScrip’s and Option Care’s talented and dedicated employees, who share a strong commitment to delivering exemplary care that makes a positive difference in people’s lives. I look forward to harnessing the strengths of both of our organizations and industry-leading teams to capitalize on the many growth opportunities this combination creates to drive long-term value for all stakeholders.”

Expected Benefits of the Transaction

• Improved, Cost-Effective Patient Care. Utilizing clinical monitoring and reporting, the combined company’s more than 2,900 skilled clinicians (pharmacists, pharmacy technicians, nurses and dieticians) will develop personalized care plans for patients and be able to provide ongoing quality care in support of complex therapy regimens. With a best-in-class platform that is national in scope, the combined company will also be positioned as the partner of choice for pharmaceutical manufacturers seeking innovative distribution channels and patient support models to access the market. Together, BioScrip and Option Care will cover 96% of the U.S. population, with facilities in 46 states and the ability to dispense and serve patients in all 50 states.
• Enhanced Scale and Therapy Offerings. The combined company will merge BioScrip’s and Option Care’s complementary portfolios and provide products that are currently only available to one of the two businesses, such as Option Care’s access to Cuvitru for the treatment of primary immunodeficiency and Nuzyra™ for the treatment of adults with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The combined company’s expanded geographic coverage, continued independence, leading quality offerings and comprehensive clinical expertise will position it to be a preferred partner for payors, providers, biopharma manufacturers and patients. Furthermore, its enhanced scale will enable it to capture scale efficiencies and create additional vectors of growth through new product and service introductions.
• Powerful Growth Engine in Attractive Industry. Home and alternate site infusion, which currently accounts for approximately 12% of the $100 billion total U.S. infusion market, is estimated to grow approximately 5-7% per year due to attractive market dynamics, including the shift to value-based care that improves clinical outcomes and delivers better results for payors and providers as well. The combined company will have the financial capacity and flexibility, scale and clinical offering diversity to drive organic growth in chronic and acute therapies along with generating growth through operational efficiencies, improved performance in revenue cycle management and innovative new therapy introductions. The combination of BioScrip and Option Care will create a diversified business across payors, therapies and geographies in which no existing payor will account for more than 11% of net revenue.
• Beneficios financieros convincentes: Se espera que la transacción impulse eficiencias significativas en las operaciones y la cadena de suministro, lo que generará más de 60 millones de dólares en sinergias netas previstas para alcanzar el pronóstico completo dentro de los 24 meses posteriores al cierre de la transacción. Se espera que estas sinergias pronosticadas y la escala mejorada de la compañía combinada con ingresos proforma de 2018 de más de $2,600 millones permitan un crecimiento de ventas y de beneficios. Además, BioScrip y Option Care han asegurado un compromiso de financiamiento con Bank of America Merrill Lynch, fondos afiliados a Ares Management Corporation y Goldman Sachs Merchant Banking Division para refinanciar y simplificar la estructura de capital de la compañía combinada, que se espera que no tenga vencimientos a corto plazo, sin capital preferente ni convenio de mantenimiento financiero. Se espera que la nueva estructura de capital proporcione a la compañía combinada un índice de apalancamiento neto combinado proforma sustancialmente más bajo, un costo de capital más bajo, una liquidez adicional significativa y un camino para continuar el apalancamiento. La compañía combinada seguirá una estrategia equilibrada de asignación de capital, continuará invirtiendo y mejorando las experiencias de los pacientes, así como a su gente y sus servicios para impulsar el crecimiento orgánico, mientras administra su perfil de deuda y continúa reduciendo el apalancamiento de manera disciplinada.

Shareholders and Management Focused on Driving Value Creation

MDP, a leading private equity firm based in Chicago, has a long and successful history investing in health care companies and partnering with them to achieve growth and significant long-term value appreciation. MDP’s notable health care investments include Ikaria Inc., Sage Products, Sirona Dental Systems, Team Health and VWR International. Option Care, formerly Walgreens Infusion Services, has been an independent company since it was separated from WBA in 2015 in a joint investment partnership between MDP funds and WBA.

Timothy P. Sullivan, a Managing Director and Head of the MDP Health Care team and a Director of Option Care, said, “We believe this transaction provides significant shareholder value creation potential and we are excited to remain a major shareholder alongside Walgreens Boots Alliance in the combined company. John, Mike and the joint leadership team bring operational expertise and strong integration track records. Since separating from Walgreens, we have made significant investments in people, process, technology and facilities. This experience, combined with their commitment to patient-centric care, should drive meaningful and long-term shareholder value.”

Rademacher and Shapiro are seasoned health care professionals with significant operational expertise and public company experience. Rademacher has held various executive-level positions at leading public healthcare companies, including Cardinal Health where he served as President and General Manager for both the Ambulatory Care Division and the Nuclear and Pharmacy Services Divisions, and at Cigna Corporation where he served as President of CareAllies and Chief Operating Officer for the CIGNA Behavioral Health business. Shapiro served as the Senior Vice President and Chief Financial Officer for Catamaran Corporation, a publicly-traded pharmacy benefits manager, and led the successful process through which the company was sold to UnitedHealth Group. He also had a longstanding career with Baxter International, holding several financial positions across several businesses and corporate functions.

Rademacher has spearheaded Option Care’s Zenith 20/20 program, which changed the company’s operating model, implementing technology, operational design and facility upgrades throughout the organization. Under his leadership, Option Care has focused on providing high-quality care and improving delivery of services to patients, payors and manufacturers. The combined company, its employees and all stakeholders are expected to benefit from a leadership team focused on creating a culture that connects its clinical expertise and company success to patient outcomes.

In addition to Rademacher and Shapiro, the combined company’s leadership will draw from the experienced teams of both Option Care and BioScrip.

The transaction, which is expected to be completed in the second half of 2019, is subject to the satisfaction of customary closing conditions, including regulatory approvals and approval by BioScrip shareholders.

Conference Call, Webcast and Presentation

BioScrip y Option Care realizarán una conferencia telefónica a las 9:00 a. m., ET, el día de la fecha, 15 de marzo de 2019, para analizar la transacción. Los números de marcación para la llamada son (877) 423-9820 (llamada gratuita en los EE. UU.) O (201) 493-6749 (internacional). Una transmisión en vivo de la conferencia telefónica y los materiales de presentación asociados estarán disponibles en la sección "Inversionistas" del sitio web de BioScrip en:www.bioscrip.com

Una reproducción en línea de la conferencia telefónica estará disponible aproximadamente dos horas después de la finalización de la conferencia telefónica en la sección Relaciones con los inversionistas del sitio web de BioScrip en: www.bioscrip.com.

Advisors

In connection with the transaction, Jefferies LLC and Moelis & Company LLC are acting as joint financial advisors to BioScrip, and Gibson, Dunn & Crutcher LLP is serving as legal advisor. Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as financial advisors and Kirkland & Ellis LLP is acting as legal advisor to Option Care.

FORWARD LOOKING STATEMENTS
Esta comunicación, además de la información histórica, contiene “declaraciones prospectivas” (como se define en la Ley de Reforma de Litigios sobre Valores Privados de 1995) con respecto, entre otras cosas, a eventos futuros o al desempeño financiero futuro de BioScrip y Option Care. Todas las declaraciones que no sean declaraciones de hechos históricos son declaraciones a futuro. Además, palabras como "anticipar", "creer", "contemplar", "continuar", "podría", "estimar", "esperar", "pretender", "puede", "planificar", "potencial" "predecir", "proyectar", "buscar", "debería", "objetivo", "hará", "haría" o la forma negativa de estas palabras, y las palabras y los términos de sustancia similar utilizados en relación con cualquier discusión sobre planes futuros, acciones o eventos identifican declaraciones prospectivas.

Forward-looking statements relating to the proposed transaction include, but are not limited to: statements about the benefits of the proposed transaction between BioScrip and Option Care, including future financial and operating results; BioScrip’s and Option Cares plans, objectives, expectations and intentions; the expected timing of completion of the proposed transaction; and other statements relating to the acquisition that are not historical facts. Forward-looking statements are based on information currently available to BioScrip and Option Care and involve estimates, expectations and projections.

Investors are cautioned that all such forward-looking statements are subject to risks and uncertainties (both known and unknown), and many factors could cause actual events or results to differ materially from those indicated by such forward-looking statements. With respect to the proposed transaction between BioScrip and Option Care, these factors could include, but are not limited to: the risk that BioScrip or Option Care may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; the risk that a condition to closing of the transaction may not be satisfied; the length of time necessary to consummate the proposed transaction, which may be longer than anticipated for various reasons; the risk that the businesses will not be integrated successfully; the risk that the cost savings, synergies and growth from the proposed transaction may not be fully realized or may take longer to realize than expected; the diversion of management time on transaction-related issues; the effect of future regulatory or legislative actions on the companies or the industries in which they operate; the risk that the credit ratings of the combined company or its subsidiaries may be different from what the companies expect; economic and foreign exchange rate volatility; and the other risks contained in BioScrip’s most recently filed Annual Report on Form 10-K.

Muchos de estos riesgos, incertidumbres y suposiciones exceden la capacidad de control o predicción de BioScrip. Debido a estos riesgos, incertidumbres y suposiciones, no debe depositar una confianza indebida en estas declaraciones prospectivas. Además, las declaraciones prospectivas se refieren solo a la información actualmente disponible para las partes en la fecha en que se realizan, y ni BioScrip ni Option Care asumen ninguna obligación de actualizar públicamente o de revisar las declaraciones prospectivas para reflejar eventos o circunstancias que puedan surgir después de la fecha de esta comunicación. Ningún punto en esta comunicación tiene la intención, o debe interpretarse, como un pronóstico de ganancias o debe interpretarse en el sentido de que las ganancias por acción de BioScrip para el año financiero actual o futuro o las de la compañía combinada, necesariamente coincidirán o excederán el histórico de ganancias publicadas por acción de BioScrip, según corresponda.

Ni BioScrip ni Option Care brindan ninguna garantía (1) de que BioScrip u Option Care alcanzará sus expectativas, o (2) con respecto a cualquier resultado o el momento de este, en cada caso, con respecto a cualquier acción regulatoria, procedimientos administrativos, investigaciones gubernamentales, litigios, cartas de advertencia, decretos de consentimiento, reducciones de costos, estrategias comerciales, ganancias o tendencias de ingresos o resultados financieros futuros. Todas las declaraciones prospectivas escritas y orales posteriores relacionadas con BioScrip, Option Care, la transacción propuesta, la compañía combinada u otros asuntos y factores atribuibles a BioScrip o a Option Care o a cualquier persona que actúe en su nombre están expresamente calificadas en su totalidad por las declaraciones de advertencia anteriores.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

BioScrip, Inc. ("BioScrip" o la "Compañía") presentará a la Comisión de Bolsa y Valores ("SEC") una declaración de poderes en relación con la transacción propuesta. La declaración de poderes contendrá información importante sobre la transacción propuesta y asuntos relacionados. SE RECOMIENDA Y SUGERIMOS A LOS INVERSIONISTAS Y TENEDORES DE VALORES QUE LEAN LA DECLARACIÓN DE PODERES CUANDO ESTÉ DISPONIBLE YA QUE CONTENDRÁ INFORMACIÓN IMPORTANTE.

La declaración de poderes y otros materiales relevantes (cuando estén disponibles) y cualquier otro documento presentado por la Compañía ante la SEC pueden obtenerse sin cargo en el sitio web de la SEC, en www.sec.gov. Además, los tenedores de valores podrán obtener copias gratuitas de la declaración de poderes y otros materiales relevantes de la Compañía comunicándose con Relaciones con Inversionistas por correo a 1600 Broadway, Suite 700, Denver, CO 80202, Attn: Investor Relations, por teléfono al (720) 697-5200, o visitando la página de Relaciones con Inversionistas de la Compañía en su sitio web corporativo en https://investors.bioscrip.com.

PARTICIPANTS IN THE SOLICITATION

Se puede considerar que la Compañía y sus directores y directivos ejecutivos participan en la solicitud de poderes de los accionistas en relación con los asuntos discutidos anteriormente. La información sobre los directores y directivos ejecutivos de la Compañía se establece en la Declaración de poderes en el Anexo 14A para la reunión anual de accionistas de la Compañía de 2018, que se presentó ante la SEC el 4 de abril de 2018. Este documento puede obtenerse gratuitamente de las fuentes indicadas anteriormente.  

La información sobre la propiedad de los directores y directivos ejecutivos de la Compañía en los valores de la Compañía se incluye en las presentaciones de la Compañía ante la SEC en los Formularios 3, 4 y 5, que se pueden encontrar en el sitio web de la SEC en www.sec.gov. Otra información con respecto a los participantes en la solicitud de poderes y una descripción de sus intereses directos e indirectos, por tenencias de valores o de otra manera, estará contenida en la declaración de poderes preliminar y la declaración de poderes definitiva y otros materiales relevantes que se presentarán ante la SEC cuando estén disponibles.

About BioScrip, Inc.

BioScrip, Inc. is one of the largest independent national providers of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Acerca de Option Care

Option Care Enterprises, Inc. (Option Care) es el proveedor de servicios de infusión en el hogar y en centros alternativos de tratamiento más grande y más confiable del país. Con acreditaciones de organizaciones de calidad de la industria como ACHC, PCAB, ASHP y URAC,* la empresa se apoya en casi 40 años de experiencia en atención clínica para ofrecer una gestión de terapia centrada en el paciente. Los servicios de infusión distintivos de Option Care comprenden la administración clínica de los medicamentos de infusión, el apoyo de enfermeros y la coordinación de la atención. El equipo multidisciplinario de más de 1,800 profesionales clínicos de Option Care, formado por farmacéuticos, enfermeros y nutricionistas, puede proporcionar cobertura de servicios de infusión en el hogar para casi todos los pacientes en los Estados Unidos que necesiten tratamiento para afecciones complejas y crónicas. Obtenga más información en www.OptionCare.com.

ORLANDO, Florida, 11 de marzo de 2019Nueva investigación realizada por Option Care Enterprises, Inc. ("Option Care"), el principal proveedor de servicios de terapia de infusión en el hogar y en sitios alternativos del país, sugiere que el método de administración de antibióticos por vía intravenosa (IV) puede mejorar el cumplimiento del paciente al tiempo que reduce los costos. El estudio [*] Wurdeman J, Decaminada G, Andrusko-Furphy K, et al. Comparison of compliance and comprehensive cost for various methods of administration of intravenous antibiotics in a home infusion setting. [Comparación del cumplimiento y el costo integral de varios métodos de administración de antibióticos intravenosos en un entorno de infusión en el hogar]. Póster presentado en la Conferencia Anual de la National Home Infusion Association (NHIA) [Asociación Nacional de la Infusión en el Hogar]; del 9 al 13 de marzo de 2019, Orlando, Florida. se presentó hoy en la Conferencia Anual de la National Home Infusion Association (NHIA) y es finalista del “Premio al Logro Abstracto Destacado.

The researchers analyzed patient compliance by comparing four techniques for antibiotic self-administration and determined ease of providing therapy was a significant factor. They concluded patients were significantly more likely to comply with therapy if they used the elastomeric pump or IV push than if they used the gravity/mini bag or electronic pump. Additionally, in many cases IV push and elastomeric pump are less costly.

“There’s a common perception that the gravity/mini bag is the least expensive method, but our research shows not only are IV push and elastomeric pump often more cost-effective, but patients find them easier to use, decreasing the likelihood that they will skip doses, which can lead to failed therapy and hospital readmission,” said Julie Wurdeman, PharmD, an Option Care infusion pharmacist and primary author of the study. “Our findings have implications for helping establish the most appropriate method of administration and underscore the value of collaboration among patients and the care team.”

The type of IV antibiotic therapy typically is chosen by the pharmacist in collaboration with the physician and determined by several factors including the medication, frequency of therapy (typically one to three times a day), rate of infusion as well as provider preference, patient lifestyle and age. The research suggests that patient compliance and cost should be factored into the equation.

Researchers studied treatment compliance in 688 Option Care home infusion patients who were treated between October 2017 and October 2018 and who missed one or more doses of IV antibiotics. They found the percentage of doses missed by technique was: 2.6 percent elastomeric pump, 2.7 percent IV push, 5 percent mini bag and 8.6 percent electronic pump.

There is a wide variation between methods in the cost of administration (factoring in equipment, compounding and patient education, but not medication), including a 209 percent difference between the least-expensive, IV push, and the most-expensive, electronic pump. The cost varies depending on the number of times per day and the rate at which the antibiotic is provided, as well as whether equipment can be reused and other factors.

In home antibiotic therapy, the patient infuses the medication through a catheter (placed by a nurse in a vein, usually in the hand or arm). The medication typically is administered one of four ways:

• IV push: The patient injects the medication via a syringe. This process is easy to learn, portable and fast.
• Elastomeric pump: The tennis ball-sized device comes pre-filled with the medication and self-squeezes it through tubing into a port the patient inserts into the catheter. This technique is easy to learn, precise and portable.
• Gravity/mini bag: The patient hangs the bag of medication on a pole and inserts the end of the tube into the catheter. The equipment involves set-up and is bulky, so it is not easily portable.
• Electronic pump: The patient connects the medication to the pump as well as the tube into the catheter and turns on the pump. The equipment involves set-up and is bulky, requiring the patient to carry the pump wherever he or she goes.

“While the type of antibiotic and rate of administration are the most important factors in determining the method of administration, in many cases there is flexibility,” said Wurdeman. “It’s important to consider all factors — including patient preference — which can help improve compliance and decrease costs.”

For its first Outstanding Abstract Achievement Award, the National Home Infusion Foundation chose abstracts that examine an innovative approach to clinical practice; identify a best practice or improve quality; are relevant to a current challenge, issue or question facing the home infusion industry; employ an effective study design/methodology to achieve results and have the ability to be expanded to a larger study.

Another Option Care study[*]Cheung K, Rout T, Banerjee U, et al. A Retrospective Evaluation of the Frequency of Vancomycin Monitoring and its Effects on Home Infusion Patients. Poster presented at the National Home Infusion Association (NHIA) Annual Conference; March 9-13, 2019, Orlando, Fla. being presented at NHIA compared results associated with frequency of therapeutic drug monitoring (TDM) among 100 patients treated with home infusion of high-dose vancomycin (a commonly prescribed antibiotic), half of whom were monitored weekly and half twice weekly. Researchers detected a potential trend that major events such as emergency department visits or hospital admissions were less prevalent among patients 55 and older who received high-dose vancomycin with twice-weekly TDM.

Acerca de Option Care

Option Care Enterprises, Inc. (Option Care) is the nation’s leading and most trusted provider of home and alternate site infusion services. Holding accreditations from industry quality organizations ACHC, PCAB, ASHP and URAC,[*]Accreditation Commission for Health Care (ACHC), Pharmacy Compounding Accreditation Board (PCAB), American Society of Health-System Pharmacists (ASHP) and URAC the company draws on nearly 40 years of clinical care experience to offer patient-centered therapy management. Option Care’s signature infusion services include the clinical management of infusion medicines, nursing support and care coordination. Option Care’s multidisciplinary team of more than 1,800 clinicians — including pharmacists, nurses and dietitians — are able to provide infusion service coverage for nearly all patients across the United States needing treatment for complex and chronic conditions. Learn more at www.OptionCare.com.